These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33529909)

  • 1. IgE antibodies to hepatitis C virus core and nonstructural antigens in chronic hepatitis C patients before and after antiviral treatment.
    Silva JPCG; Jesus LS; Isabel Schinoni M; Oliveira IS; Atta MLBS; Atta AM
    Int Immunopharmacol; 2021 Apr; 93():107405. PubMed ID: 33529909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in hepatitis C virus (HCV)-specific CD8 T-cell phenotype during pegylated alpha interferon and ribavirin treatment are related to response to antiviral therapy in patients chronically infected with HCV.
    Caetano J; Martinho A; Paiva A; Pais B; Valente C; Luxo C
    J Virol; 2008 Aug; 82(15):7567-77. PubMed ID: 18480446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
    Chu CM; Sheen IS; Liaw YF
    Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.
    Cramp ME; Rossol S; Chokshi S; Carucci P; Williams R; Naoumov NV
    Gastroenterology; 2000 Feb; 118(2):346-55. PubMed ID: 10648463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early predictive efficacy of core antigen on antiviral outcomes in genotype 1 hepatitis C virus infected patients.
    Feng B; Yang RF; Zhang HY; Luo BF; Kong FY; Rao HY; Jin Q; Cong X; Wei L
    Braz J Infect Dis; 2015; 19(4):390-8. PubMed ID: 26100438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C.
    Sanjo M; Saito T; Ishii R; Nishise Y; Haga H; Okumoto K; Ito J; Watanabe H; Saito K; Togashi H; Fukuda K; Imai Y; El-Shamy A; Deng L; Shoji I; Hotta H; Kawata S
    J Med Virol; 2010 Aug; 82(8):1364-70. PubMed ID: 20572079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteome-wide anti-hepatitis C virus (HCV) and anti-HIV antibody profiling for predicting and monitoring the response to HCV therapy in HIV-coinfected patients.
    Burbelo PD; Kovacs JA; Ching KH; Issa AT; Iadarola MJ; Murphy AA; Schlaak JF; Masur H; Polis MA; Kottilil S
    J Infect Dis; 2010 Sep; 202(6):894-8. PubMed ID: 20684729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of specific antibodies to HCV-ARF/CORE+1 protein in patients treated with pegylated interferon plus ribavirin.
    Karamitros T; Kakkanas A; Katsoulidou A; Sypsa V; Dalagiorgou G; Mavromara P; Hatzakis A
    J Viral Hepat; 2012 Mar; 19(3):182-8. PubMed ID: 22329372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
    Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
    Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients.
    Zhang Y; Liu Y; Zhao Y; Shi L; Ma L; Yan H; Wu H; Wei L; Dong T; Chen X
    Liver Int; 2012 Jan; 32(1):102-9. PubMed ID: 22098382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin.
    Perrella A; Sbreglia C; Atripaldi L; Esposito C; D'Antonio A; Perrella O
    Scand J Gastroenterol; 2010; 45(2):250-5. PubMed ID: 19968615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in hepatitis C virus (HCV) antibody status in patients with chronic hepatitis C after eradication of HCV infection by interferon therapy.
    Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kuzuya T; Honda T; Hayashi K; Nakano I; Katano Y; Goto H
    Clin Infect Dis; 2005 Mar; 40(6):e49-54. PubMed ID: 15736006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative antibody responses to structural (Core) and nonstructural (NS3, NS4, and NS5) hepatitis C virus proteins among seroconverting injecting drug users: impact of epitope variation and relationship to detection of HCV RNA in blood.
    Beld M; Penning M; van Putten M; Lukashov V; van den Hoek A; McMorrow M; Goudsmit J
    Hepatology; 1999 Apr; 29(4):1288-98. PubMed ID: 10094977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody.
    Maylin S; Martinot-Peignoux M; Ripault MP; Moucari R; Cardoso AC; Boyer N; Giuily N; Castelnau C; Pouteau M; Asselah T; Nicolas-Chanoine MH; Marcellin P
    Liver Int; 2009 Apr; 29(4):511-7. PubMed ID: 19076273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical responders to antiviral therapy of chronic HCV infection show elevated antiviral CD4+ and CD8+ T-cell responses.
    Pillai V; Lee WM; Thiele DL; Karandikar NJ
    J Viral Hepat; 2007 May; 14(5):318-29. PubMed ID: 17439521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection.
    Di Bisceglie AM; Janczweska-Kazek E; Habersetzer F; Mazur W; Stanciu C; Carreno V; Tanasescu C; Flisiak R; Romero-Gomez M; Fich A; Bataille V; Toh ML; Hennequi M; Zerr P; Honnet G; Inchauspé G; Agathon D; Limacher JM; Wedemeyer H
    Gastroenterology; 2014 Jul; 147(1):119-131.e3. PubMed ID: 24657484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
    Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
    J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for immune activation in patients with residual hepatitis C virus RNA long after successful treatment with IFN and ribavirin.
    Radkowski M; Opoka-Kegler J; Cortes KC; Bukowska-Ośko I; Perlejewski K; Pawełczyk A; Laskus T
    J Gen Virol; 2014 Sep; 95(Pt 9):2004-2009. PubMed ID: 24920726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative analysis of specific Th1/Th2 helper cell responses and IgG subtype antibodies in interferon-alpha-treated patients with chronic hepatitis C.
    Hempel G; Galle PR; Löhr HF
    J Med Virol; 2001 Jul; 64(3):340-9. PubMed ID: 11424124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
    Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
    J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.